Today: 22 March 2026
Subscribe
Browse Category

NYSE:LLY 18 December 2025 - 28 December 2025

Eli Lilly Stock (LLY) Outlook for Monday: Latest Deal Headlines, GLP-1 Pill Race, and Wall Street Targets

Eli Lilly Stock (LLY) Outlook for Monday: Latest Deal Headlines, GLP-1 Pill Race, and Wall Street Targets

Eli Lilly shares closed near record highs Friday at $1,077.75, with trading volume muted ahead of the weekend. ABL Bio announced it expects a $40 million upfront payment and $15 million equity investment from Lilly tied to their Grabody platform collaboration. The deal targets obesity and muscle diseases. Novo Nordisk’s oral Wegovy approval this week intensified competition in the obesity drug market.
28 December 2025
··
Eli Lilly Stock (LLY) Update: Latest Price, Fresh Headlines, Analyst Forecasts, and What to Watch Before Markets Reopen

Eli Lilly Stock (LLY) Update: Latest Price, Fresh Headlines, Analyst Forecasts, and What to Watch Before Markets Reopen

Eli Lilly shares ended Friday at $1,077.75, near record highs, as the market weighed strong demand for obesity drugs against rising pricing and access pressures. Novo Nordisk’s FDA approval for an oral Wegovy pill this week put pressure on Lilly, whose own oral therapy is expected in 2026. The stock’s equity value remains around $1 trillion. U.S. markets reopen Monday, with traders watching for weekend developments.
27 December 2025
·
Eli Lilly Stock (LLY) Holds Near $1,078 After Friday’s Close as GLP‑1 Pricing, Pill Competition, and Retatrutide Data Shape the 2026 Outlook

Eli Lilly Stock (LLY) Holds Near $1,078 After Friday’s Close as GLP‑1 Pricing, Pill Competition, and Retatrutide Data Shape the 2026 Outlook

Eli Lilly shares closed Friday near $1,077.75, little changed after a narrow session. The Centers for Medicare & Medicaid Services this week announced a plan to expand GLP‑1 drug access, capping monthly costs at $50 for Medicare beneficiaries. A Trump-era pricing deal also sets lower reference prices for weight-loss drugs. Investors are watching policy shifts as key drivers for LLY’s valuation.
27 December 2025
··
Eli Lilly Stock (LLY) Today: GLP‑1 Price Cuts, the Obesity Pill Race, and What Investors Are Watching Into 2026

Eli Lilly Stock (LLY) Today: GLP‑1 Price Cuts, the Obesity Pill Race, and What Investors Are Watching Into 2026

Eli Lilly shares traded near $1,075 Friday afternoon, down 0.2% in thin post-Christmas trading as U.S. indexes hovered close to record highs. The stock moved between $1,068 and $1,082 amid muted volume. The NYSE and Nasdaq remained open for a regular session. Investors continue to watch Lilly’s pricing moves and its lead in obesity and diabetes treatments.
26 December 2025
··
Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

Abivax (NASDAQ: ABVX) rose about 5.3% to $145.31 in premarket trading Friday, with U.S. markets the main venue as Euronext remained closed for St. Stephen’s Day. The stock has surged in December amid Eli Lilly takeover rumors, recent inclusion in the Nasdaq Biotechnology Index, and ongoing interest in its ulcerative colitis drug obefazimod.
26 December 2025
···
Eli Lilly (LLY) Stock: Key News, Catalysts, Forecasts and Risks to Watch Before the Dec. 26, 2025 Market Open

Eli Lilly (LLY) Stock: Key News, Catalysts, Forecasts and Risks to Watch Before the Dec. 26, 2025 Market Open

Eli Lilly stock last traded at $1,076.98 before the holiday break, with after-hours pricing at $1,077.97. Trading resumes Friday amid new U.S. policy moves to expand GLP-1 drug coverage and push prices lower, including a CMS model and TrumpRx pricing plan. Investors are watching for price swings as thinner holiday-week liquidity meets headline risk.
26 December 2025
··
Eli Lilly (LLY) Stock After Hours Today (Dec. 25, 2025): Holiday Pause, GLP‑1 Catalysts, and What to Watch Before the Market Opens Dec. 26

Eli Lilly (LLY) Stock After Hours Today (Dec. 25, 2025): Holiday Pause, GLP‑1 Catalysts, and What to Watch Before the Market Opens Dec. 26

Eli Lilly shares closed at $1,076.98 after the early NYSE close on Dec. 24, with after-hours quotes near $1,077–$1,078 in thin holiday trading. U.S. exchanges remained shut Dec. 25 for Christmas. The 52-week range stands at $623.78 to $1,111.99. Trading volume is expected to rise when markets reopen Friday, with attention on GLP-1 policy and competition.
25 December 2025
·
Eli Lilly (LLY) Stock After Hours on Dec. 24, 2025: Christmas Eve Close, GLP‑1 Headlines, and What to Watch Before Markets Reopen

Eli Lilly (LLY) Stock After Hours on Dec. 24, 2025: Christmas Eve Close, GLP‑1 Headlines, and What to Watch Before Markets Reopen

Eli Lilly shares closed up 0.50% at $1,076.98 in light Christmas Eve trading, then slipped to $1,071.74 after hours amid thin volume. The move followed news that U.S. regulators plan to expand Medicaid and Medicare coverage for GLP‑1 obesity drugs, including Lilly’s Zepbound, with a $50 monthly cap for Medicare starting January 2027.
24 December 2025
···
Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly shares rose 0.47% to $1,076.67 in light Christmas Eve trading, with volume just over 200,000 shares by late morning. Investors focused on new GLP-1 headlines, including regulatory updates and global expansion, as well as a Reuters report showing Lilly’s Mounjaro outpacing Novo’s Wegovy in India since March. Indian generics are expected to intensify competition as patent expiries approach.
24 December 2025
···
Eli Lilly Stock (LLY) After Hours Today (Dec. 23, 2025): What Happened After the Bell—and What to Watch Before the Market Opens Dec. 24

Eli Lilly Stock (LLY) After Hours Today (Dec. 23, 2025): What Happened After the Bell—and What to Watch Before the Market Opens Dec. 24

Eli Lilly shares closed down 0.45% at $1,071.64 on Tuesday after the FDA approved Novo Nordisk’s Wegovy pill, the first oral GLP‑1 drug for chronic weight management in the U.S. Novo shares rose on the news, while Lilly stock traded flat in after-hours. Investors focused on the competitive impact of the new oral treatment on Lilly’s obesity franchise. Trading volume reached about 2 million shares.
23 December 2025
··
Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

Eli Lilly shares hovered near record highs Tuesday after the FDA approved Novo Nordisk’s first oral Wegovy pill, intensifying rivalry in the obesity drug market. LLY traded around $1,077 as investors weighed Novo’s launch against Lilly’s own oral candidate, orforglipron, which could reach the market in 2026. Both firms have signaled lower pricing for new pills as competition heats up.
23 December 2025
···
Eli Lilly Stock (LLY) Outlook on Dec. 23, 2025: Novo’s Wegovy Pill, Lilly’s Next Catalysts, and Wall Street Forecasts

Eli Lilly Stock (LLY) Outlook on Dec. 23, 2025: Novo’s Wegovy Pill, Lilly’s Next Catalysts, and Wall Street Forecasts

Eli Lilly shares traded near $1,076 after the FDA approved Novo Nordisk’s first daily oral Wegovy for obesity. Novo plans a U.S. launch in January 2026, beating Lilly’s own oral candidate, which remains under review. Novo shares rose on the news; Lilly slipped slightly. Analysts expect oral obesity drugs could reach 20% of the market by 2030.
23 December 2025
··
Novo Nordisk (NVO) Stock Jumps After FDA Approves Wegovy Pill: Today’s News, Analyst Forecasts, and 2026 Catalysts (23 December 2025)

Novo Nordisk (NVO) Stock Jumps After FDA Approves Wegovy Pill: Today’s News, Analyst Forecasts, and 2026 Catalysts (23 December 2025)

The FDA approved Novo Nordisk’s oral Wegovy pill for chronic weight management in the U.S., marking the first oral GLP-1 agonist cleared for this use. Shares jumped on the news, lifting European healthcare stocks. The company reported 16.6% mean weight loss in trials when taken as prescribed. Novo plans to launch the pill in the U.S. in early January 2026.
23 December 2025
···
Eli Lilly Stock (LLY) After Hours Drops on Wegovy Pill Approval: What to Know Before the Market Opens Dec. 23, 2025

Eli Lilly Stock (LLY) After Hours Drops on Wegovy Pill Approval: What to Know Before the Market Opens Dec. 23, 2025

Eli Lilly shares closed up 0.47% at $1,076.48 Monday, then fell about 1% in after-hours trading after the FDA approved Novo Nordisk’s Wegovy weight-loss pill. Novo’s U.S. shares jumped roughly 6% following the news. The new oral semaglutide is the first FDA-cleared pill for obesity, with Novo saying it will launch early next year at $149 a month. Lilly’s own oral obesity drug, orforglipron, could be approved as soon as late March.
23 December 2025
····
ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

Abivax shares jumped about 10% to $126 in early U.S. premarket trading after reports of renewed takeover speculation involving Eli Lilly and confirmation of Abivax’s addition to the Nasdaq Biotechnology Index. French media said Lilly representatives met with France’s Treasury about a possible acquisition, though Reuters could not confirm the meeting. Both companies declined to comment on the rumors.
22 December 2025
····
Eli Lilly (LLY) Stock: What to Know Before the U.S. Market Opens on Dec. 22, 2025

Eli Lilly (LLY) Stock: What to Know Before the U.S. Market Opens on Dec. 22, 2025

Eli Lilly shares closed at $1,071.44 on Dec. 19, near record highs, as new late-stage data for oral GLP-1 candidate orforglipron showed less weight regain versus placebo after switching from injectables. Retatrutide posted 28.7% average weight loss in a Phase 3 trial. Lilly cut Zepbound prices in the U.S. and Canada. Orforglipron could receive FDA approval as early as March 2026.
22 December 2025
··
Eli Lilly Stock Week Ahead (Dec. 22–26, 2025): LLY Enters Holiday Week With Obesity-Drug Catalysts, Pricing Headlines, and Policy Risk

Eli Lilly Stock Week Ahead (Dec. 22–26, 2025): LLY Enters Holiday Week With Obesity-Drug Catalysts, Pricing Headlines, and Policy Risk

Eli Lilly shares closed at $1,071.44 on Friday, Dec. 19, up 4.3% from the previous week. The company’s stock remains near record highs as late-stage trial data showed its oral obesity drug orforglipron helped patients maintain weight loss after switching from injectables. Reuters reported the FDA is considering a faster review timeline for orforglipron.
21 December 2025
··
Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Eli Lilly shares closed at $1,071.44 on Dec. 19, near record highs, after reporting positive Phase 3 results for its oral weight-loss drug orforglipron. The company also cut prices on Zepbound and Mounjaro in the U.S. and Canada. Lilly’s market value surpassed $1 trillion this year amid growing demand for obesity and cardiometabolic treatments.
20 December 2025
···
Eli Lilly Stock After Hours (Dec. 19, 2025): LLY Closes Higher on Obesity-Pill Momentum—What to Watch Before the Next Market Open

Eli Lilly Stock After Hours (Dec. 19, 2025): LLY Closes Higher on Obesity-Pill Momentum—What to Watch Before the Next Market Open

Eli Lilly shares closed at $1,071.44 on Friday, Dec. 19, up 1.38%, then edged up just 0.08% after hours. The move followed Phase 3 trial results showing orforglipron, Lilly’s oral GLP-1 drug, helped maintain weight loss after injectable therapies. Lilly confirmed FDA submission for obesity treatment. Expedited review could bring a decision by March 2026.
20 December 2025
···
Eli Lilly Stock (LLY) After Hours Today (Dec. 18, 2025): Orforglipron Headlines, Analyst Forecasts, and What to Watch Before Friday’s Open

Eli Lilly Stock (LLY) After Hours Today (Dec. 18, 2025): Orforglipron Headlines, Analyst Forecasts, and What to Watch Before Friday’s Open

Eli Lilly shares closed up 1.45% at $1,056.88 Thursday after reporting positive Phase 3 results for its oral obesity drug orforglipron. Patients switching from injectable GLP-1 drugs maintained weight loss, with those from Wegovy averaging 0.9 kg change and those from Zepbound 5 kg. The stock held steady in after-hours trading. Detailed trial data will be released later.
18 December 2025
···
1 … 5 6 7 8 9 … 12

Stock Market Today

  • Tenaz Energy (TSX:TNZ) Valuation Under Spotlight After Profit Turnaround
    March 22, 2026, 12:11 PM EDT. Tenaz Energy (TSX:TNZ) posted a net income of CA$315.61 million in 2025, recovering from prior losses, with sharp production gains driving a 49.35% one-month and 158.57% year-to-date share price surge. Despite these gains, its price-to-earnings (P/E) ratio stands at a modest 6.9, below the Canadian Oil and Gas sector average of 18.8. Revenue forecasts suggest 25.6% annual growth, but earnings are projected to decline 41.2% annually over three years, raising questions about sustained valuation gaps. A discounted cash flow (DCF) model estimates intrinsic value at CA$358.16 per share, far above the current CA$67.85 price, highlighting a potential mispricing. Investors must balance the optimistic turnaround with risks including heavy revenue dependence on the Netherlands and declining future earnings.
Go toTop